IL4 and Alzheimer disease: These results suggest that keratinocytes are the major target of dupilumab in AD, and that IL-4/13 signaling in keratinocytes is essential for the inflammatory loop of type 2 EIME in AD, regardless of the persistent activation of DCs and T lymphocytes.